Across TCGA pan-cancer cohorts, PTGIR Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PTGIR data layer compared with 24 for mass-spec protein.
The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher PTGIR Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PTGIR expression acts as an unfavorable survival marker.
CESC, ESCA, and UCEC are the cancer types where PTGIR Mutation most reproducibly stratifies survival.